PharmNovo appoints CFO and Clinical Lead to strengthen the organisation
PharmNovo AB, a Swedish pharmaceutical company developing drugs for neuropathic pain, announces that the company has strengthened the team entering the clinical phase. Tommy Nilsson takes on the role of CFO, and Jarkko Kalliomäki will support clinical management and work with the design and development of clinical studies.
In August, PharmNovo started clinical studies of its drug candidate PN6047 for the treatment of neuropathic pain, so-called nerve pain, after raising SEK 73 million in a share issue led by Sciety earlier this summer.
Tommy Nilsson has a background as CFO at subsidiaries of Electrolux and Ericsson. He has worked as interim CFO for businesses in several industries for the past years. At PharmNovo, he will lead financial management and reporting, build up the company's routines and processes, and prepare the company for future follow-on financing.
Jarkko Kalliomäki is a specialist in pain and pain relief and holds an MD in Physiology. He has over ten years of experience as a Senior Clinical Research Physician at AstraZeneca R&D in Södertälje in several pain-related projects. Jarkko works as a consultant in rehabilitation medicine and pain relief at, among others, Sophiahemmet, PBM, and St. Göran's Hospital. He will support clinical management and work with the design and development of the clinical studies in close collaboration with Olof Breuer, CMO at PharmNovo.
"We welcome Tommy Nilsson and Jarkko Kalliomäki to our team. Their knowledge and experience are tailor-made to strengthen the positive development of PharmNovo as we now take the step from preclinical to clinical development. Both Tommy and Jarkko have the right skills to help establish PharmNovo as a sustainable, growth-oriented pharmaceutical company and achieve our vision of improving the quality of life of people suffering from chronic pain," says Per von Mentzer, CEO of PharmNovo.
For more information, please contact:
Per von Mentzer, CEO
Phone +46 705 44 32 50
Email: per.von.mentzer@pharmnovo.com
About PharmNovo
PharmNovo AB is a clinical phase pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. In this area, there is currently a lack of sufficient treatment. The company's drug candidate, PN6047, has effectively reduced nerve pain in animal models in preclinical studies. The company also sees clinical potential in other areas such as migraine, anxiety/depression, and chronic cough. PharmNovo, headquartered in Medicon Village in Lund, Sweden, was founded in 2008 by Dr Bengt von Mentzer, who has more than 30 years of experience in drug development and pain research at Astra Zeneca. The team comprises prominent researchers in academia and industry, and the company has an extensive international network of leading expert advisors. To learn more, visit pharmnovo.com.
Tags:
